Analysts expect Ascentage Pharma Group International to report revenue of 122.12 M for 2026, against a range of 115.52 M to 128.72 M. The most recent reported year, 2025, came in at 83.24 M, a 14.5% beat against the 72.72 M consensus.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 4.39 M | 30.72 M | 30.71 M | 135.01 M | 83.24 M | - | - | ||
| High Estimate | 6.55 M | 31.17 M | 55.47 M | 172.89 M | 76.07 M | 128.72 M | 252.40 M | ||
| Low Estimate | 5.63 M | 26.38 M | 49.48 M | 149.58 M | 69.38 M | 115.52 M | 229.12 M | ||
| Consensus Estimate | 6.09 M | 28.78 M | 52.47 M | 161.24 M | 72.72 M | 122.12 M | 240.76 M |
Analysts expect Ascentage Pharma Group International to report earnings per share of -0.52 for 2026, against a range of -0.55 to -0.49. The most recent reported year, 2025, came in at -2.02, a 53.0% miss against the -1.32 consensus.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -1.93 | -1.96 | -1.82 | -0.74 | -2.02 | - | - | ||
| High Estimate | -1.56 | -1.68 | -1.56 | -0.22 | -1.28 | -0.49 | -0.43 | ||
| Low Estimate | -1.84 | -1.84 | -1.90 | -0.26 | -1.36 | -0.55 | -0.51 | ||
| Consensus Estimate | -1.70 | -1.76 | -1.73 | -0.24 | -1.32 | -0.52 | -0.47 |
Pull Wall Street consensus for Ascentage Pharma Group International (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/estimates?ticker=AAPG&mode=revenue&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/estimates"
params = {"ticker": "AAPG", "mode": "revenue", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/estimates?ticker=AAPG&mode=revenue&api_key=YOUR_API_KEY");
const data = await res.json();